Verapamil SR

Phase 2Small molecule

MMedical University of Graz

Verapamil SR is one of 35 small molecule programs targeting Type 1 Diabetes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 DiabetesActive, not recruiting

Type 1 DiabetesPhase 2

Active, not recruiting

Competition

Competitive Landscape

79 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

6 2

Stelara

Johnson & Johnson

Phase 3

1 3

Inpefa

LLexicon Pharmaceuticals

Phase 3

5 4

Tricor

JJagotec

Phase 3

2 5

Diamox

Teva

Phase 2

2 6

Humira

Novartis

Phase 2

1 7

Kerendia

Bayer

Phase 2

1 8

Teplizumab

Sanofi

Phase 3

9 9

Prolia

OOrganon and Co

Phase 2

1 10

Bacillus Calmette-Guérin

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes1 trial

Verapamil SR in Adults With Type 1 Diabetes

Active, not recruiting·MMedical University of Graz·Phase 2·NCT04545151·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Verapamil SR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Verapamil SR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Verapamil SR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Graz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMedical University of Graz

Verapamil SR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News